Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when ZVRA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsZevra Therapeutics announces Q1 2026 earnings results and schedules investor call
Filed May 6, 2026 · Period ending May 6, 2026 · ~1 min read
Key Changes
-
medium
Company issued press release with Q1 2026 financial results and corporate updates for quarter ended March 31, 2026
Item 7.01 view on EDGAR → -
medium
Earnings conference call scheduled for May 6, 2026 at 4:30 p.m. ET to discuss quarterly results and provide business updates
Item 7.01 view on EDGAR → -
low
Financial details contained in furnished press release (Exhibit 99.1), not filed as part of official SEC record
Item 9.01 verify on EDGAR →
Summary
Zevra Therapeutics disclosed its first quarter 2026 financial results through a press release on May 6, 2026, and scheduled an earnings conference call for the same day at 4:30 p.m. Eastern Time. This is a routine quarterly earnings announcement that pharmaceutical companies make to update investors on financial performance and business developments.
Retail investors should review the actual press release (Exhibit 99.1) and listen to the earnings call for specific financial metrics, revenue figures, drug development updates, and management commentary on the business outlook. The 8-K filing itself is procedural and doesn't contain the substantive financial data. Watch for any guidance changes, clinical trial updates for the company's drug pipeline, or commentary on commercial performance during the earnings call, as these factors typically drive stock movement for biotech companies like Zevra.
Section-by-Section Diff
Event · Item 2.02 — Results of Operations and Financial Condition
Zevra announced Q1 2026 financial results via press release and scheduled earnings call for May 6, 2026 at 4:30 p.m. ET.
Added in current filing · verify on EDGAR →
On May 6, 2026, Zevra Therapeutics, Inc., a Delaware corporation ("Zevra" or "the Company"), issued a press release announcing its financial results and corporate updates for the first quarter ended March 31, 2026, as well as information regarding a conference call and audio webcast to discuss its financial results and corporate updates scheduled for Wednesday, May 6, 2026, at 4:30 p.m. ET.
The company disclosed its first quarter 2026 financial results through a press release and scheduled an earnings call for the same day at 4:30 p.m. ET. The actual financial details are contained in the press release (Exhibit 99.1), which is furnished but not filed with the SEC.
Event · Item 9.01 — Financial Statements and Exhibits
Zevra Therapeutics filed an 8-K attaching a press release dated May 6, 2026; no material event details disclosed in the filing body.
Added in current filing · verify on EDGAR →
Press Release dated May 6, 2026
The 8-K references a press release dated May 6, 2026, filed as Exhibit 99.1. The filing body does not disclose the content or subject matter of the press release, so the nature and materiality of the event cannot be determined from this 8-K alone. Investors should review Exhibit 99.1 directly to understand what was announced.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 8, 2026 · How we verify